Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 16/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 16/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23014919 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP3A4 | |
| Ammonia Solution, Strong SCHEMBL29828187 | 0.99 | CYP2D6 (1.00) | CYP2D6CYP3A4 | |
| SCHEMBL29828022 | 0.97 | CYP2D6 (0.98) | CYP2D6CYP3A4 | |
| SCHEMBL29828211 | 0.97 | CYP2D6 (0.98) | CYP2D6CYP3A4 | |
| SCHEMBL29827764 | 0.95 | CYP2D6 (0.93) | CYP2D6CYP3A4 | |
| SCHEMBL29828122 | 0.95 | CYP2D6 (0.93) | CYP2D6CYP3A4 | |
| SCHEMBL24722303 | 0.94 | CYP3A4 (0.88) | CYP2D6CYP3A4 | |
| SCHEMBL29828042 | 0.94 | CYP3A4 (0.88) | CYP2D6CYP3A4 | |
| Ammonia Solution, Strong SCHEMBL29828519 | 0.93 | CYP3A4 (0.88) | CYP2D6CYP3A4 | |
| SCHEMBL24722126 | 0.93 | CYP2D6 (0.86) | CYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2022-09-22 | — | — | US | disclosed |
| EP-4017499-A1 | NUCLEOSIDE PRODRUGS AND USES RELATED THERETO | Emory University (US) | 2022-06-29 | — | — | EP | disclosed |
| WO-2021035214-A1 | NUCLEOSIDE PRODRUGS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2021-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | PNPO, GSTO1, CYP2C18 | CYP2D6 18/4885CYP3A4 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.